Promimic AB is a Sweden-based biomaterial company. The Company manufactures, markets and sells biomaterials for improved osseointegration (bone healing) to the companies in the markets for orthopedic and dental implants. The Company operates primarily in the United States, Europe, and South America, with current product applications in the dental, spine, total joint, extremities, and sports medicine implant markets.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
23/10/26	SEK 9.000	-5.76%	2,387
21/10/26	SEK 9.550	0.00%	1,000
20/10/26	SEK 9.550	-3.54%	101
19/10/26	SEK 9.900	+3.66%	500
16/10/26	SEK 9.550	-2.05%	225

Delayed Quote Nasdaq Stockholm

More quotes

Market Closed - Nasdaq Stockholm 17:00:00 23/10/2026 BST			5-day change	1st Jan Change
9.000 ^SEK	-5.76%		-7.69%	-46.90%

08-20	Promimic AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-19	Promimic Q1 2026 operating loss at SEK 3.5 mln	RE

Market Cap	170M 17.13M 15.29M 14.13M 12.8M 23.96M 1.63B 24.35M 67.32M 852M 64.28M 62.91M 2.69B	P/E 2024	-33.7x	P/E 2025	-36.6x
Enterprise Value	149M 15.05M 13.44M 12.42M 11.25M 21.05M 1.43B 21.4M 59.15M 749M 56.48M 55.28M 2.36B	EV / Sales 2024	7.85x	EV / Sales 2025	6.74x
Free-Float	23.31%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Nasdaq Stockholm	PRO	Delayed
Deutsche Boerse AG	B0T	Delayed
Börse Stuttgart	B0T	Delayed
Boerse Muenchen	B0T	Real-time

08-20	Promimic AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-19	Promimic Q1 2026 operating loss at SEK 3.5 mln	RE
05-19	Promimic AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-16	Promimic nomination committee proposes new chairman	RE
02-24	Promimic Q4 net sales SEK 11.5 mln	RE
02-24	Promimic AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
11-19	Promimic Q3 sales of SEK 12.9 mln	RE
11-19	Promimic AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
22/08/25	Promimic AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
11/06/25	Promimic's CFO Heidi Bader makes a minor share purchase	FW
15/05/25	Promimic reports slightly lower operating loss	FW
15/05/25	Promimic Q1 Sales Increase 1.4% To 8.8 Msek	RE
15/05/25	Promimic AB Reports Earnings Results for the First Quarter Ended March 31, 2025	CI

Promimic AB Share Price

Stocks

PRO

SE0017487242

Biotechnology & Medical Research

Valuation: Promimic AB

Chart: Promimic AB

Latest news: Promimic AB

Analysts' recommendations: Promimic AB

Press Releases: Promimic AB

Quotes and Performance

Price Extremes

Managers and Directors: Promimic AB

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

1 day	-5.76%
1 week	-7.69%
Current month	-11.76%
1 month	-7.22%
3 months	-10.00%
6 months	-15.09%
Current year	-46.90%

1 week	9	9.9
1 month	9	10.3
Current year	7.7	16.55
1 year	7.7	19.45
3 years	7.7	45
5 years	7.7	45
10 years	7.7	45

Manager	Title	Age	Since
Per Gunnar Kjellin CTO	Chief Tech/Sci/R&D Officer	54	31/12/2003
Magnus Larsson CEO	Chief Executive Officer	63	17/01/2017
Heidi Bader DFI	Director of Finance/CFO	45	31/12/2022

Director	Title	Age	Since
Helena Maria Brisby BRD	Director/Board Member	61	31/12/2020
Johan Dighed BRD	Director/Board Member	53	31/12/2020
Pehr Abrahamsson CHM	Chairman	59	20/05/2026

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/10/24	Magnus Larsson	Exercice	Chief Executive Officer	16,000	0.0869%
11/10/24	Magnus Larsson	Exercice	Chief Executive Officer	160,000	0.8685%
11/10/24	Magnus Larsson	Sell	Chief Executive Officer	125,000	0.6785%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PROMIMIC AB	-5.76%	-7.69%	-34.78%	-66.79%	18.19M
WUXI APPTEC CO., LTD.	+2.41%	-6.33%	+43.43%	+71.02%	63.29B
ARGENX SE	-0.15%	+3.11%	+10.29%	+72.56%	54.89B
LONZA GROUP AG	+0.57%	+4.64%	+12.82%	+89.79%	53.28B
IQVIA HOLDINGS INC.	+0.37%	+3.07%	+28.23%	+51.53%	45.81B
BEONE MEDICINES AG	-1.21%	+0.95%	+20.44%	+128.58%	43.46B
REVOLUTION MEDICINES, INC.	-0.37%	-1.20%	+252.94%	+568.54%	40.23B
CELLTRION, INC.	+0.05%	+6.75%	+14.48%	+56.75%	33.45B
WUXI BIOLOGICS (CAYMAN) INC.	+1.19%	-5.84%	+27.86%	-0.65%	23.7B
GENMAB A/S	-0.38%	+4.55%	+37.71%	+28.10%	23.76B
Average	-0.33%	+0.09%	+41.34%	+99.94%	38.19B
Weighted average by Cap.	+0.38%	+0.55%	+48.17%	+122.11%

	2024	2025
Net sales	48.91M 4.93M 4.4M 4.06M 3.68M 6.89M 468M 7M 19.36M 245M 18.49M 18.1M 773M	44.42M 4.47M 4M 3.69M 3.35M 6.26M 425M 6.36M 17.59M 223M 16.79M 16.44M 702M
Net income	-12.55M -1.26M -1.13M -1.04M -945K -1.77M -120M -1.8M -4.97M -62.88M -4.74M -4.64M -198M	-8.75M -882K -787K -727K -659K -1.23M -83.71M -1.25M -3.47M -43.86M -3.31M -3.24M -138M
Net Debt	-35.76M -3.6M -3.22M -2.97M -2.69M -5.04M -342M -5.12M -14.16M -179M -13.52M -13.23M -565M	-20.63M -2.08M -1.86M -1.71M -1.55M -2.91M -197M -2.95M -8.17M -103M -7.8M -7.63M -326M